

References

I-20

1. Synagis® (palivizumab)[package insert]. Gaithersburg, MD:MedImmune, LLC;07/2010.
2. Paes BA, Mitchell A, Banerji A, et al. A decade of respiratory syncytial virus epidemiology and prophylaxis: Translating evidence into everyday clinical practice. *Can Respir J*. 2011; 18(2).
3. Paes BA, Mitchell A, Banerji A, et al. A decade of respiratory syncytial virus epidemiology and prophylaxis: Translating evidence into everyday clinical practice. *Can Respir J*. 2011;18(2).
4. Robinson KA, Odelola OA, Saldanha IJ, McKoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. *Cochrane Database Syst Rev*. 2012;(2).
5. Hynicka LM, Ensor Pharmd CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients (April). *Ann Pharmacother*. 2012.
6. Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: A systematic review and additional economic modeling of subgroup analyses. *Health Technol Assess*. 2011;15(5):1-124.
7. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. *N Engl J Med*. 2013;368(19):1791-9.
8. Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. *Cochrane Database Syst Rev*. 2013;30;4
9. Costello H, Ray W, Chaiwatpongsakorn S, et al. Targeting RSV with vaccines and small molecule drugs. *Infect Disord Drug Targets*. 2012;12(2):110-128.
10. Robinson J. Respiratory syncytial virus and palivizumab: Where are we in 2014? *Can J Infect Dis Med Microbiol*. 2014;11-12.
11. Resch B. Respiratory syncytial virus infection in high-risk infants-an update on palivizumab prophylaxis. *Microbiol J*. 2014;71-77.
12. Wegzyn C, Toh LK, Notario G, et al. Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: A systematic review. *Infect Dis Ther*. 2014;133-158.
13. American Academy of Pediatrics (AAP). Updated guidance for Palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *AAP*. 2014;415-420.
14. Chu, H. Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children. *Influenza and Other Respiratory Viruses*. 2016: 205-210.
15. Ozyurt, A. Efficacy of Palivizumab Prophylaxis Among Infants With Congenital Heart Disease: A Case Control Study. *Pediatric Pulmonology*. 2015; 50:1025–1032.

16. Zembles, T. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital. *Am J Health-Syst Pharm.* 2016; 73(6): 405-408.
17. Hayes, Inc. Hayes Technology Assessment. Palivizumab (Synagis) Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Infants. Landsdale, PA: Hayes, Inc.; November 2018.